AC Immune SA
IPOPrecision medicine for neurodegenerative diseases
Public · Switzerland · $78.1M raised
- Business Model
- B2B
- Website
- acimmune.com
- Total Funding
- $78.1M
- Last Round
- $43.5M Private EquityDec 2016
- Rounds
- 3
- Type
- Public
About
Clinical-stage biopharmaceutical company and global leader in developing precision medicine for neurodegenerative diseases.
Summary
AC Immune SA is a Biotech company based in Switzerland. It has raised $78.1M in total across 3 rounds, most recently a $43.5M Private Equity round in Dec 2016. Investors include Goldman Sachs, Morgan Stanley and SVB Leerink.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2016
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.